alleging they illegally drove up drug prices. Apart from pharmacy benefit managers, the FTC says Eli Lilly, Sanofi and Novo Nordisk have control over the insulin market, and all three companies ...

In its complaint, the FTC alleges that PBMs followed a “chase-the-rebate strategy,” which led to soaring insulin list prices and made it harder for Americans to get the crucial medication ...

Insulin prices have skyrocketed in recent years, working a hardship on the growing number of diabetics in the US. Progressive ...

The FTC accuses major PBMs of inflating insulin prices, impacting patient costs and access to affordable medications. PBMs prioritize high-rebate drugs, contributing to high insulin prices and ...

The FTC believes that the PBMs participated in unjust competition and practices, incentivizing manufacturers to increase insulin list prices. “Express Scripts intends to vigorously defend itself to ...

in the US for operating a "perverse drug rebate system" that it claims artificially inflated the prices of insulin products. The lawsuit – which has been anticipated since the FTC published a ...

No matter what happens in this election, the government should work for the people. The government may not be perfect, but it ...

One exception that enjoys bipartisan support, however, is the effort to rehab the drug supply chain. It’s currently dominated ...